Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

Today, the Lung Cancer Research Foundation, in collaboration with Bayer Pharmaceuticals, announced submissions are being ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...